The multivariate analysis revealed that after adjustment for age, ischemic heart disease, chronic kidney disease, SpO2 during oxygen therapy and CRP when administering HFNO, the predictive value of death and ineffectiveness of HFNO therapy was high—AUC 0.851 and 0.800, respectively (Table 5). The gene discussed is CRP; the disease is chronic kidney disease.